Pay in 4 interest-free payments of $8.75 Learn more
Ships within 48 hours · Estimated delivery Oct 22 - Oct 27
A phase I/II clinical trial evaluating abiraterone in advanced breast cancer patients is also underway
InChi: InChI=1S/C20H23BCl2N2O9/c1-10(2)5-14(21-33-19(32)20(34-21
Maddali MV
Glycogen synthase kinase-3β inhibition ameliorates cardiac parasympathetic dysfunction in type 1 diabetic Akita mice
Inhibition of the prostaglandin-degrading enzyme 15-PGDH potentiates tissue regeneration
DY-131 - CAS# 95167-41-2 60200 A phase I/II clinical trialDY131, also known as GSK 9089, CAS No. 95167 41 2, is a novel selective agonist at estrogen related receptors ERR and ERR. DY131 could potentiate the ERRgamma induced growth inhibition in LNCaP ERRgamma and DU145 ERRgamma cells in a dose dependent manner. ERRgamma may perform an antiproliferative or tumor suppressing function in prostate cancer cells. ERRgamma could be a novel therapeutic target for prostate cancer treatment. Product information CAS